Assuntos
Degeneração Hepatolenticular , Complicações na Gravidez , Adolescente , Ensaios Enzimáticos Clínicos , Feminino , Degeneração Hepatolenticular/diagnóstico , Degeneração Hepatolenticular/tratamento farmacológico , Humanos , Testes de Função Hepática , Gravidez , Complicações na Gravidez/diagnóstico , Complicações na Gravidez/tratamento farmacológico , Transaminases/sangue , Sulfato de Zinco/administração & dosagem , Sulfato de Zinco/uso terapêuticoRESUMO
No disponible
Assuntos
Gravidez , Adolescente , Feminino , Humanos , Complicações na Gravidez , Degeneração Hepatolenticular , Sulfato de Zinco , Transaminases , Testes de Função Hepática , Ensaios Enzimáticos ClínicosRESUMO
No disponible
Assuntos
Idoso , Masculino , Humanos , Actinomyces , Abscesso Hepático , Testes de Função HepáticaRESUMO
OBJECT: To evaluate the effectiveness of Ranitidine i.v. versus Omeprazole i.v. for gastrointestinal bleeding of peptic origin. MATERIAL AND METHODS: Prospective, comparative, randomized and open study of 81 in-patients, hospitalized consecutively during 13 months, with gastrointestinal bleeding of peptic origin and signs of recent hemostasis (S.R.H.), belonging to the groups Forrest Ib and II. Treatment groups: group A: Ranitidine: initial injection of 50 mg. i.v., followed by 100 mg/6 hours i.v., during the first 72 hours and afterwards by 150 mg/12 hours, orally; group B: Omeprazole: initial injection of 80 mg. i.v., followed by 40 mg/8 hours i.v. during the first 72 hours and afterwards by 20 mg/24 hours, orally. Evaluation criteria: persistent haematemesis and melena; need for transfusions: treatment failure average period of hospitalization and disappearance of S.R.H. after 72 hours. RESULTS: 43 patients received Ranitidine and 38 Omeprazole. Both groups were homogeneous in regard to variables ar hospitalization. No significant differences were found between these two groups: persistent melena (26% group A vs. 8% group B); patients who needed transfusion (39% vs. 31%); treatment failure (19% vs. 5%); average period of hospitalization; and disappearance of S.R.H. (81% vs. 95%). None of the patients died. CONCLUSIONS: The effectiveness of Ranitidine i.v. and Omeprazole i.v., in the dosage used and in a selected group of patients with gastrointestinal bleeding, is similar. However, there is a trend to register less treatment failures and a higher percentage of S.R.H. disappearance with the patients treated with Omeprazole. Further studies with more patients are necessary to confirm this tendency.
